Relmada Therapeutics Inc (RLMD)

Dec 15, 2025

Relmada Therapeutics updates executive contracts and increases salaries By Investing.com - Investing.com Nigeria

Dec 15, 2025

Dec 15, 2025

Relmada Therapeutics Amends Executive Employment Agreements - TipRanks

Dec 15, 2025

Dec 15, 2025

Relmada Therapeutics updates executive contracts and increases salaries - Investing.com

Dec 15, 2025

Dec 14, 2025

What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in

Dec 14, 2025

Dec 13, 2025

Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn

Dec 13, 2025

Dec 11, 2025

Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World

Dec 11, 2025

Dec 09, 2025

Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com

Dec 09, 2025

Dec 06, 2025

Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq

Dec 06, 2025

Dec 04, 2025

Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser

Dec 04, 2025

Dec 04, 2025

Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser

Dec 04, 2025

Dec 04, 2025

Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser

Dec 04, 2025

Dec 04, 2025

Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success - MSN

Dec 04, 2025

Dec 03, 2025

Relmada’s bladder cancer therapy shows 92% complete response rate By Investing.com - Investing.com Nigeria

Dec 03, 2025

Dec 03, 2025

Relmada’s bladder cancer therapy shows 92% complete response rate - Investing.com India

Dec 03, 2025

Dec 03, 2025

Relmada Therapeutics Advances NDV-01 for Non-Muscle Invasive Bladder Cancer with Positive Phase 2 Follow-Up Data - Quiver Quantitative

Dec 03, 2025

Dec 03, 2025

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewswire

Dec 03, 2025

Dec 03, 2025

A History of Outperforming Analyst Forecasts and Beating the Odds: Relmada Therapeutics Inc (RLMD) - setenews.com

Dec 03, 2025

Dec 03, 2025

Why Relmada Therapeutics Inc. (4E2) stock stays resilientRecession Risk & Trade Opportunity Analysis - Newser

Dec 03, 2025

Dec 02, 2025

Relmada Therapeutics (RLMD) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 02, 2025

What risks investors should watch in Relmada Therapeutics Inc. stockTrade Ideas & Fast Moving Trade Plans - Newser

Dec 02, 2025

Nov 29, 2025

How supply chain issues affect Relmada Therapeutics Inc. stockQuarterly Earnings Report & Long-Term Growth Plans - moha.gov.vn

Nov 29, 2025

Nov 27, 2025

Relmada Therapeutics Inc. (US75955J4022.SG) Balance Sheet - Yahoo! Finance Canada

Nov 27, 2025

Nov 27, 2025

Relmada Therapeutics Announces $100 Million Underwritten Offering - globallegalchronicle.com

Nov 27, 2025

Nov 26, 2025

Relmada Therapeutics Inc 4E2 Stock Analysis and ForecastVolume Analysis Techniques & Rapid Portfolio Trading - earlytimes.in

Nov 26, 2025

Nov 26, 2025

Pullback Watch: Is Relmada Therapeutics Inc. stock supported by innovation pipelineWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn

Nov 26, 2025

Nov 26, 2025

Is Relmada Therapeutics Inc. stock supported by strong cash flows - BỘ NỘI VỤ

Nov 26, 2025

Nov 26, 2025

Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - Markets Financial Content

Nov 26, 2025

Nov 25, 2025

Views of Wall Street’s Leading Experts on Relmada Therapeutics Inc - Setenews

Nov 25, 2025

Nov 24, 2025

Relmada Therapeutics Inc. (RLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 24, 2025

Nov 24, 2025

Relmada cut to neutral by Mizuho on Phase 3 study failure - MSN

Nov 24, 2025

Nov 21, 2025

Relmada Therapeutics, Inc. (RLMD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Nov 21, 2025

Nov 21, 2025

How risky is Relmada Therapeutics Inc. stock now2025 Key Lessons & Growth Focused Entry Reports - newser.com

Nov 21, 2025

Nov 20, 2025

How Relmada Therapeutics Inc. (4E2) stock trades in high volatilityEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com

Nov 20, 2025

Nov 20, 2025

This Stock Is Up 704% in 2025 But Has No Products to Its Name - inkl

Nov 20, 2025

Nov 20, 2025

Will Relmada Therapeutics Inc. stock sustain high P E ratiosCEO Change & Consistent Growth Equity Picks - newser.com

Nov 20, 2025

Nov 19, 2025

Is Relmada Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Mizuho upgrades Relmada Therapeutics stock to Outperform on NDV-01 potential - Investing.com Nigeria

Nov 19, 2025

Nov 19, 2025

Smart tools for monitoring Relmada Therapeutics Inc.’s price actionWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Mizuho Upgrades Relmada Therapeutics (RLMD) - Nasdaq

Nov 19, 2025

Nov 19, 2025

Will Relmada Therapeutics Inc. (4E2) stock outperform small cap peers - newser.com

Nov 19, 2025

Nov 19, 2025

What valuation ratios show for Relmada Therapeutics Inc. (4E2) stock - newser.com

Nov 19, 2025

Nov 19, 2025

Mizuho Upgrades RLMD to 'Outperform', Raises Price Target | RLMD Stock News - GuruFocus

Nov 19, 2025

Nov 19, 2025

Relmada Therapeutics (RLMD) Receives Upgrade with Significant Up - GuruFocus

Nov 19, 2025

Nov 19, 2025

Relmada Therapeutics upgraded by Mizuho with a new price target - Quantisnow

Nov 19, 2025